Back to Search
Start Over
Biomarkers in oncology drug development
- Source :
- Molecular Oncology. 3:24-32
- Publication Year :
- 2008
- Publisher :
- Wiley, 2008.
-
Abstract
- Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. For those drugs taken forward, biomarker measurements may also help choose the appropriate dose, schedule and patient population. In this review we discuss the intrinsic properties of biological sample based efficacy measurements and how these relate to their implementation in oncology drug development by way of points to consider and examples.
- Subjects :
- Drug
Cancer Research
medicine.medical_specialty
Drug Industry
business.industry
Chemistry, Pharmaceutical
media_common.quotation_subject
Reviews
General Medicine
Pharmacology
Patient population
Oncology
Drug Design
Genetics
Animals
Humans
Molecular Medicine
Medicine
Oncology drug
Biomarker (medicine)
Medical physics
business
Biomarkers
media_common
Subjects
Details
- ISSN :
- 15747891
- Volume :
- 3
- Database :
- OpenAIRE
- Journal :
- Molecular Oncology
- Accession number :
- edsair.doi.dedup.....9cc2260d039688c20afcfc68dd702f1b
- Full Text :
- https://doi.org/10.1016/j.molonc.2008.12.002